Drug Profile
DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation
Alternative Names: BK-1310; MT 2355Latest Information Update: 14 Apr 2022
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer BIKEN; Mitsubishi Tanabe Pharma Corporation
- Class Bacterial vaccines; Haemophilus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Phase III Bacterial meningitis
Most Recent Events
- 11 Apr 2022 Preregistration for Diphtheria (In children, In infants, Prevention, In volunteers) in Japan (IM)
- 11 Apr 2022 Preregistration for Diphtheria (In children, In infants, Prevention, In volunteers) in Japan (SC)
- 11 Apr 2022 Preregistration for Haemophilus infections (In children, In infants, Prevention, In volunteers) in Japan (IM)